Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Investigating the role of Brca1 mutations in ovarian fibrosis
EF 2020-21
Résumé
ovarian cancer is the most lethal form of gynecological malignancy, with 63 being the average age of onset. However, for women that are carriers of BRCA1 mutations the average age of onset drops down to 42, significantly reducing quality of life. It is known that scarring of the ovarian tissue (fibrosis) poses as a risk factor for ovarian cancer by creating a pro-tumour environment in the aging ovary, allowing metastasized cancer cell to grow. Fibrosis is the overaccumulation of ordered collagen fibers (an extracellular matrix protein). Fibroblasts, which are a cell type that is found in connective tissue and is responsible for creating an extracellular matrix (ECM). However, BRCA1 mutation carriers tend to develop ovarian fibrosis at a much young (premenopausal). It is currently unknown how BRCA1 accelerates the rate of ovarian fibrosis. We hypothesize that mouse ovarian fibroblasts (MOF) with Brca1 mutations have enhanced activation that results in increased production of structural proteins, such as collagen, thereby accelerating the risk of ovarian cancer by creating pre-metastatic niches. We wish to determine if Brca1 knock out (KO) MOF exhibit enhanced activation in response to their activator (transforming growth factor-β), as compared wild-type MOF, in vitro. Followed by creating an in vivo model of Brca1 mutation induced ovarian fibrosis, and ultimately study the role that metformin (an anti-diabetic drug that has been shown to abrogate fibrosis) in both above-mentioned, in vitro and in vivo models of Brca1 induced ovarian fibrosis. These results would shed light on its potential use in a prophylactic manner to delay the onset of ovarian cancer in BRCA1 mutation carriers, significantly improving the quality of life of these women.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449803
Name
Vaishnav Het
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the role of Brca1 mutations in ovarian fibrosis
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brca1 Mutations; Collagen; Extra-Cellular Matrix; Fibroblast Activation; Metformin; Ovarian Cancer; Ovarian Fibroblasts; Ovarian Fibrosis; Post-Menopausal; Tgf-Beta
Abstract
ovarian cancer is the most lethal form of gynecological malignancy, with 63 being the average age of onset. However, for women that are carriers of BRCA1 mutations the average age of onset drops down to 42, significantly reducing quality of life. It is known that scarring of the ovarian tissue (fibrosis) poses as a risk factor for ovarian cancer by creating a pro-tumour environment in the aging ovary, allowing metastasized cancer cell to grow. Fibrosis is the overaccumulation of ordered collagen fibers (an extracellular matrix protein). Fibroblasts, which are a cell type that is found in connective tissue and is responsible for creating an extracellular matrix (ECM). However, BRCA1 mutation carriers tend to develop ovarian fibrosis at a much young (premenopausal). It is currently unknown how BRCA1 accelerates the rate of ovarian fibrosis. We hypothesize that mouse ovarian fibroblasts (MOF) with Brca1 mutations have enhanced activation that results in increased production of structural proteins, such as collagen, thereby accelerating the risk of ovarian cancer by creating pre-metastatic niches. We wish to determine if Brca1 knock out (KO) MOF exhibit enhanced activation in response to their activator (transforming growth factor-β), as compared wild-type MOF, in vitro. Followed by creating an in vivo model of Brca1 mutation induced ovarian fibrosis, and ultimately study the role that metformin (an anti-diabetic drug that has been shown to abrogate fibrosis) in both above-mentioned, in vitro and in vivo models of Brca1 induced ovarian fibrosis. These results would shed light on its potential use in a prophylactic manner to delay the onset of ovarian cancer in BRCA1 mutation carriers, significantly improving the quality of life of these women.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Vaishnav, Het
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~